Objective: The aim of this study was to estimate the prevalence of menopausal symptoms in relation to treatment modalities in Asian women treated for breast cancer.
D uring the menopausal transition, women commonly experience a variety of symptoms that affect their quality of life (QOL) and may require medical treatment, 1,2 such as hormone therapy (HT). 3, 4 Menopausal symptoms may also be precipitated by cancer treatments. 5<7 Numerous studies have shown that white women with breast cancer frequently experience severe menopausal symptoms after receiving treatment, particularly chemotherapy and ta-moxifen. 8<10 Among postmenopausal breast cancer patients, hot flashes were observed in 46% to 65%, night sweats in 36%, and vaginal dryness in 48%. 11, 12 A similarly high prevalence of menopausal symptoms 9, 13 has been reported in women who were premenopausal at the time of breast cancer diagnosis and treatment, and these symptoms are likely to reflect overall reproductive health. 14<16 The prevalence of menopausal symptoms varies by geographic region and by the ethnicity of the population. 17 Few studies have examined menopausal symptoms among Asian women. The Study of Women's Health Across the Nation found that Chinese and Japanese women reported significantly fewer menopausal symptoms than white women. 18 In the Pan-Asia Menopause study, the prevalence of menopausal symptoms varied substantially across ethnic groups. Asian women were more likely to experience body aches or joint aches and pains (76%-93%) and less likely to complain of hot flashes or vasomotor symptoms than were their Western counterparts. 19 Little data exists regarding menopausal symptoms in Asian women who received treatment for primary breast cancer.
In this study, we examined the prevalence of menopausal symptoms in a large, population-based prospective study of breast cancer survival conducted among urban Chinese women and evaluated the relationship between these symptoms and recent cancer treatments. We focused on the most common symptoms, namely, hot flashes, night sweats, and vaginal dryness, and evaluated the demographic, lifestyle, and medical correlates of these symptoms.
METHODS

Study population
The Shanghai Breast Cancer Survival Study is a large, population-based, longitudinal study of women who were diagnosed with primary breast cancer between the ages of 25 and 70 years in Shanghai, China. Incident breast cancer cases were identified between April 2002 and December 2006 from the population-based Shanghai Cancer Registry. Cancer diagnoses were confirmed by medical record review; detailed methods have been published elsewhere. 20 Briefly, 6,303 patients who met the study inclusion criteria were identified. The inclusion criteria were as follows: (1) a first diagnosis of primary breast cancer, (2) permanent resident of Shanghai, and (3) alive at study recruitment. Of the eligible women, 757 (12%) refused to participate, 258 (4.1%) were visiting other cities, 83 (1.3%) could not be contacted, and 159 (2.5%) were excluded for miscellaneous reasons such as health or communication problems that prevented them from participating in the initial survey at 6 months post-diagnosis. A total of 5,046 women participated in the study and provided written informed consent (participation rate, 80.1%). In this analysis, 23 women who had stage IV cancer at the time of the interview were excluded, leaving a total of 5,023 participants. The institutional review boards of all participating institutions approved the study protocol.
Data collection
Information on demographic factors, personal and firstdegree family history of cancer, other chronic diseases, reproductive factors, lifestyle, diet, use of complementary and alternative medicine, and QOL was collected through in-person interviews conducted by trained staff using a structured questionnaire. Two previously validated, generic QOL instruments, the Medical Outcome Study of Quality of Life and the Short-Form Health Survey were used to assess the health-related QOL among breast cancer survivors. The first 2,232 participants were administered the Medical Outcome Study of Quality of Life, and the remaining 2,814 participants were administered the Short-Form Health Survey. 21 During the interviews, anthropometric measurements were taken, including height, weight, waist circumference, and hip circumference. Body mass index (BMI) and waist-to-hip ratio were calculated from these measurements. Clinical and pathology information was collected, including the stage of disease at the time of breast cancer diagnosis, hormone receptor status (tumor estrogen receptor [ER] and progesterone receptor [PR] expression), and primary treatments (surgery/mastectomy, radiation therapy, chemotherapy, immunotherapy, and/or hormonal therapy such as tamoxifen). Medical charts were reviewed to verify clinical and treatment information. Commonly used chemotherapeutic drugs included cytoxan, doxorubicin (Adriamycin) and 5fluorouracil, docetaxel (Taxotere), epirubicin-Adriamycin and vinorelbine (Navelbine), and immunotherapy (interferon, interleukin, and thymosin).
Detailed information was collected on menopausal symptoms by asking: BHave you ever experienced any of the following menopausal symptoms since having breast cancer, such as hot flashes, night sweats, or vaginal dryness?[ Those who answered Byes[ to one of these symptoms were considered to have Bany menopausal symptom.[ Participants were also asked for dates of onset/end and, if applicable, resolution of each symptom. Almost all women reported that they had menopausal symptoms since having breast cancer and that they continued to experience menopausal symptoms at 6 months after breast cancer diagnosis and treatment. Women who answered Byes[ to having symptoms were asked about treatments or methods used regularly (three times per week constantly since having breast cancer) to alleviate these symptoms. We plan to evaluate and publish an analysis of the treatment information in the future.
Statistical analysis
The sociodemographic, lifestyle, and clinical characteristics of women with and without menopausal symptoms were compared using the Cochran-Mantel-Haenszel statistics or analysis of variance with adjustment for age at diagnosis (categories). Unconditional logistic regression was used to derive odds ratios (ORs) and 95% CIs to measure the association between menopausal symptoms with various cancer treatment modalities, with adjustment for potential confounders. Factors included in the model were age at breast cancer diagnosis (continuous), education, number of live births (0, 1, or Q2), current marital status (married/living with partner vs single/widowed or divorced/separated), waist-to-hip ratio (quartiles), menopause status (premenopause and postmenopause), history of chronic disease (yes/no), perceived QOL (poor, average, or good), stage of disease (tumor-node-metastasis classification 0-I, II, and III), hormone receptor status of the tumor (ER+/PR+, ERj/PRj, mixed [ERj/PR+ or ER+/PRj], or unknown), and treatment for breast cancer (mastectomy, radiotherapy, chemotherapy, immunotherapy, and/or tamoxifen use). Menopause was defined as Bcessation of menstruation for 12 months or longer, excluding lapses due to pregnancy and breastfeeding.[ 22 All statistical tests were based on two-tailed probability and a significance level of > less than 0.05. Breast cancer cases were also grouped into three categories based on the number of menopausal symptoms that women experienced: those without any symptoms and those with one or two or more symptoms. Polychotomous logistical regression analysis was applied to evaluate the association of number of menopausal symptoms with cancer treatments using women without any symptoms as the reference.
To evaluate the association of breast cancer treatments with individual menopausal symptoms in the context of the endogenous estrogen environment, we conducted analyses stratified by menopause status (premenopause vs postmenopause) and BMI (normal vs overweight/obese) using the World Health Organization definition of obesity (Q25.0 kg/m 2 ). 23 We also conducted analyses stratified by selfreported history of chronic disease (coronary heart diseases, stroke, hypertension, diabetes mellitus, bronchitis, asthma, gastritis, and hepatitis; yes/no) and overall perceived QOL (poor vs average vs good). Tests for interaction were performed by using the log-likelihood test. All statistical analyses were performed using SAS software, version 9.1 (SAS Institute, Cary, NC).
RESULTS
The characteristics of breast cancer patients at 6 months post-diagnosis in relation to reported menopausal symptoms Table 1 . The median time since diagnosis was 6.4 months. A total of 56.0% of women reported one or more menopausal symptoms during the first 6 months after diagnosis. The median age of cancer patients at diagnosis was 51.1 years. The mean (TSD) age was lower among women experiencing any menopausal symptoms (51.7 T 8.5 y) than among those who did not experience any menopausal symptoms (55.7 T 11.4 y). Women with and without menopausal symptoms had similar educational attainment, income, and exercise participation and did not differ significantly regarding smoking or alcohol consumption habits. Compared with women who did not experience any menopausal symptoms, women with symptoms were more likely to be premenopausal or to have one child (P G 0.01 for both) and to report poor QOL or a history of chronic disease (P G 0.01 for both). They were also more likely to have received immunotherapy or tamoxifen for breast cancer treatment (P G 0.01 for both) and to have hormone receptorYpositive tumors (P = 0.01) than were asymptomatic women. The prevalence of HT use was low among women in this study and did not differ according to the presence or absence of menopausal symptoms.
The numbers and prevalences of each individual menopausal symptom are presented in Table 2 by age and menopause status of women at breast cancer diagnosis. Premenopausal women were more likely to be symptomatic than were postmenopausal women (67.2% vs 46.3%, respectively). The highest prevalence of reporting any menopausal symptom was in women 46 to 55 years of age (,70%) and decreased to 34% in women older than 65 years (P G 0.01). The highest prevalence of reporting any symptom occurred in premenopausal women older than 45 years (71%-75%) and in the younger groups of postmenopausal women (60%-63%). The prevalence of each individual menopausal symptom in our population was as follows: 2,218 (44%) for hot flashes, 1,777 (35%) for night sweats, and 460 (9%) for vaginal dryness. Premenopausal women were more likely than postmenopausal women to experience hot flashes (55% vs 34%) or night sweats (43% vs 28%; P G 0.05 for all).
Reporting of individual symptoms also varied across age groups. Hot flashes, night sweats, and vaginal dryness were more prevalent in women 46 to 55 years of age than in other age groups of women, regardless of menopause status (P G 0.01 for all, except for vaginal dryness among premenopausal women ( Table 2) .
Multivariate logistic regression analyses controlling for age at diagnosis, education, number of live births, marital status, perceived QOL status, a history of chronic disease, menopause status, and clinical characteristics showed that chemotherapy, immunotherapy, and tamoxifen were each positively and independently associated with menopausal symptoms. The associations between these treatments and each individual menopausal symptom, such as hot flashes and night sweats, were statistically significant (Table 3 ). Radiation treatment was not significantly associated with menopausal symptoms in this population. Stratified analyses showed that chemotherapyrelated menopausal symptoms were confined to women who were premenopausal at the time of breast cancer diagnosis. These women were more likely to report any and individual menopausal symptoms after chemotherapy. Adjusted ORs (OR adj ) for the association of chemotherapy with each individual menopausal symptom in this subgroup were 2.23 (95% CI, 1.35-3.67) for hot flashes, 2.55 (95% CI, 1.47-4.40) for night sweats, and 3.32 (95% CI, 1.12-9.83) for vaginal dryness. In contrast, women treated with chemotheraphy who were postmenopausal at cancer diagnosis did not experience a significant increase in any of these symptoms ( Table 3) .
The risk of experiencing any menopausal symptom increased with tamoxifen use among all women (OR adj , 1.63; 95% CI, 1.42-1.87), and the types of symptoms reported in premenopausal and postmenopausal women did not differ appreciably. Premenopausal women treated with tamoxifen reported a nearly 1.8-fold increase in hot flashes and night sweats (OR adj , 1.78; 95% CI, 1.44-2.21, and OR adj , 1.79; 95% CI, 1.43-2.24, respectively). Vaginal dryness was also modestly increased after tamoxifen therapy, but these associations did not reach statistical significance (OR adj , 1.25; 95% CI, 0.88-1.78). Among women who were postmenopausal at the time of breast cancer diagnosis, the prevalence of reporting any menopausal symptom and each individual Table 3 ). We also examined the association across BMI groups (G25.0 kg/m 2 vs Q25.0 kg/m 2 ) and found no differences. However, the risk of experiencing each individual menopausal symptom with tamoxifen use was higher among younger women (age at diagnosis, G50 y) with BMI of 25.0 kg/m 2 or greater (data not shown). Immunotherapy in both premenopausal and postmenopausal women with breast cancer was associated with an increased risk of each individual menopausal symptom (OR adj range, 1.3-1.5; P G 0.05 for any and each individual symptom in premenopausal women, and OR adj range, 1.3-1.8; P G 0.05 for any and each individual symptom in postmenopausal women). Prevalence and ORs for number of menopausal symptoms (0, 1, and/or Q2) associated with specific breast cancer treatment modalities are presented in Table 4 . Overall, premenopausal women were more likely to experience two or more symptoms than were postmenopausal women (37.1% vs 20.6%). Radiation therapy was not associated with the number of menopausal symptoms experienced, regardless of menopause status. Women reported an increased frequency of two or more symptoms after chemotherapy (OR adj , 1.48; 95% CI, 1.10-1.98, in all women). However, this association was significant only among premenopausal women (OR adj , 1.75; 95% CI, 1.00-3.05, for one symptom, and OR adj , 1.77; 95% CI, 1.54-4.98, for Q2 symptoms; P interaction = 0.05). Both immunotherapy and tamoxifen use were associated with an increased risk of experiencing two or more menopausal symptoms in all women (OR adj , 1.47 and 1.74, respectively), and the risk of developing one symptom with tamoxifen use was slightly higher among premenopausal women (OR adj , 1.74; 95% CI, 1.36-2.23) than among postmenopausal women (OR adj , 1.39; 95% CI, 1.11-1.73); however, the difference was not significant across the subgroups (P interaction = 0.87).
Furthermore, we examined the association between number of menopausal symptoms and breast cancer adjuvant treatment in analyses stratified by BMI (normal [less than 25.0] versus overweight/obese [25.0 kg/m 2 or greater]). History of chronic diseases (yes vs no), and perceived QOL (poor vs average vs good QOL). Approximately 35% of participants in the study population were overweight or obese, and this group was more likely to experience two or more menopausal symptoms than were normal-weight women (30.2% vs 25.7%; P G 0.01). Overweight/obese women had an increased risk of experiencing menopausal symptoms with use of chemotherapy compared with normalweight women (OR adj , 1.92; 95% CI, 1.22-3.03 vs OR adj , 1.03; 95% CI, 0.88-1.44, for one symptom). Similarly, the association between tamoxifen use and experiencing several symptoms was stronger among overweight/obese women than among normal-weight women (OR adj , 2.1 vs 1.6 for Q2 symptoms). In contrast, use of immunotherapy was significantly and positively associated with experiencing menopausal symptoms among normal-weight women, but the association was weak in overweight/obese women. Overall, interaction tests between menopausal symptoms and all In analyses stratified by history of chronic disease, the prevalence of experiencing menopausal symptoms did not differ significantly between breast cancer patients with and without a history of chronic diseases (56.3% vs 55.4%). Although the risk of developing two or more symptoms with chemotherapy was higher among women without (OR adj , 2.84; 95% CI, 1.13-7.14) than those with a history of chronic disease (OR adj , 1.37; 95% CI, 1.00-1.88), the difference was not statistically significant (P interaction = 0.29). On the other hand, the positive association between tamoxifen use and occurrence of two or more menopausal symptoms was stronger among women with a history of chronic disease than among women without (OR adj , 1.95; 95% CI, 1.61-2.36 vs OR adj , 1.31; 95% CI, 0.94-1.83). Again, the test of interaction was not statistically significant (P interaction 9 0.05).
Women who reported poor QOL were more likely than those reporting average or good QOL to report any menopausal symptom (59.4%, 56.5%, or 52.6%, respectively; P = 0.03) and two or more symptoms (29.3% vs 24.1%; P = 0.005). The OR of experiencing two or more menopausal symptoms with tamoxifen use varied across the categories of QOL (OR adj , 2.14 95; 95% CI, 1.19-3.96, for poor; OR adj , 1.83; 95% CI, 1.51-2.21, for average QOL; and OR adj , 1.17; 95% CI, 0.78-1.75, for good QOL, respectively; P interaction = 0.06). The associations between chemotherapy and immunotherapy with number of menopausal symptoms did not differ by QOL category (data not shown).
DISCUSSION
In this study, we found that Chinese women treated for primary breast cancer had a high prevalence of menopausal symptoms, which is similar to results reported from studies conducted in Western countries with largely white populations. 6, 11, 24 Similar to other studies, the occurrence of menopausal symptoms was not affected by education, income, or lifestyle factors, including smoking, alcohol use, or physical activity. 6 The median age of natural menopause was approximately 49 years in this population. 25 We found that perimenopausal women and women who had recently undergone menopause had the highest prevalence of menopausal symptoms. We also found that, in general, premenopausal women had a higher prevalence of menopausal symptoms than postmenopausal women. 26, 27 Hot flashes were the most common symptom experienced by our participants, with a prevalence of 44.2% for all women, 55.0% for premenopausal women, and 33.7% for postmenopausal women. This rate was lower compared with the 65% or higher prevalence rate found among white women with breast cancer aged 40 to 65 years. 6, 11, 12 We also found that the prevalence of specific menopausal symptoms varied across age groups and menopause status. The lowest prevalence of hot flashes (26%) occurred among women 40 years or younger, mainly among premenopausal cancer patients, which was much lower compared with the same group of white women (46%). 13 The highest occurrence of hot flashes or night sweats was observed among women aged 46 to 55 years, which is consistent with a previous report by Ganz et al, 15 in which hot flashes and night sweats were highest among breast cancer patients 45 to 51 years of age compared with younger patients. In general, hot flashes, night sweats, and vaginal dryness were higher in the oldest group of premenopausal women (46-55 y) and in the younger groups of postmenopausal women (G55 y); these symptoms decreased with age in the latter case.
In our study, breast cancer patients were at increased risk of experiencing any and each individual menopausal 28, 29 case-control studies, 9, 30 and cross-sectional 6, 31, 32 studies in women who received treatment for primary breast cancer in Western countries. The association between chemotherapy and menopausal symptoms (any and each individual symptom) was more pronounced among premenopausal compared with postmenopausal women, 33 reflecting the premature ovarian failure induced by chemotherapy in premenopausal women. 26, 34 The biological mechanism underlying vasomotor symptoms such as hot flashes and night sweats is still unclear. However, vasomotor symptoms have been correlated with the acute decline in estrogen levels in the body 35, 36 that occurs as a result of natural menopause or the reduced ovarian reserve induced by chemotherapy or adjuvant tamoxifen therapy, which, in turn, leads to early onset of menopause in premenopausal women. 26, 37 We speculate that because women 45 to 55 years of age (ie, those closer to biological menopause) experience dramatic changes in their ovarian function due to the reduction in primordial ovarian follicles, they are more susceptible to ovarian suppression or estrogen deficiency when they undergo adjuvant treatments and are thus more likely to experience menopausal symptoms than other age groups of women.
In this study, both premenopausal and postmenopausal breast cancer patients who received tamoxifen experienced one or more menopausal symptoms than patients who had not received tamoxifen. These findings are in agreement with reports from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention trial 28 and the Wisconsin Tamoxifen Trial, 38 in which tamoxifen recipients experienced a higher prevalence of night sweats, hot flashes, and genitourinary symptoms than the placebo group. The use of tamoxifen was associated with an increased risk of vaginal dryness among postmenopausal women but not premenopausal women in our study.
Carpenter et al 39 reported severe hot flashes with tamoxifen use among younger women with a higher BMI, which is consistent with the findings of our study. The occurrence of multiple symptoms (Q2) was much higher among breast cancer patients who received tamoxifen, in particular among postmenopausal women, overweight/obese women, and women with a history of chronic disease and self-perceived poor QOL. Some studies have reported associations between weight gain and physiological distress with use of adjuvant therapy, namely, chemotherapy 40 or tamoxifen, 10,41 among breast cancer patients, although other studies have not found such an association. 26 In addition, previous studies reported that comorbidity has an effect on the occurrence of distress and health-related QOL 42 and survivorship 43 in breast cancer patients. Consistent with the findings of previous studies, 5,6,39 self-reported overall QOL was strongly associated with reporting of menopausal symptoms in this study and modified the association of adjuvant treatments and tamoxifen use with menopausal symptoms. Detailed analyses on menopausal symptoms and various domains of QOL among the breast cancer patients in our study are ongoing, and results will be published in the future.
In our observation, women who had immunotherapy were more likely to experience menopausal symptoms, regardless of menopause status, obesity, the presence of comorbidity, or QOL categories. We found no previous reports on immunotherapy and menopausal symptoms. We cannot exclude the possibility that the adverse associations we found are due to chance, given the multiple comparisons involved, particularly considering that relatively few women (15%) were involved in this analysis. More studies on the effects of immunotherapy on menopausal symptoms are needed.
It is important to interpret our results in the context of the limitations of this study. Information bias may have led to overreporting of the types of menopausal symptoms because women experiencing more symptoms may have been more likely to respond to questions about menopausal symptoms. However, this bias is likely to be minimal because all participants responded to the questions. In addition, information bias may have led to misreporting of the types of symptoms, because data on menopausal symptoms are, by definition, subjective and must be based on self-reports. Recall bias must also be considered, but the short duration between disease occurrence, cancer treatment, and the interview suggests that our study participants are likely to have accurately recalled their menopausal symptoms and treatments received; thus, any misclassification is likely to have been random. Although our questionnaire includes the common menopausal symptoms reported previously, the questionnaire has not been validated in the study population. Furthermore, we did not collect information on menopausal symptoms that participants experienced before breast cancer diagnosis and treatment. This precluded us from evaluating differences in menopausal symptoms occurring before and after breast cancer diagnosis.
Our study also has several noticeable strengths. To our knowledge, this is the first and largest population-based study to investigate the prevalence of menopausal symptoms in relation to breast cancer treatment among Chinese women, a population with very different lifestyle and dietary risk factors and a much lower prevalence of HT use than that of white women or women residing in Western countries. The selection bias and recall bias were minimized in this study because of the high participation rate and the use of an interviewer-administered questionnaire. The large sample size and extensive information collected on socioeconomic, lifestyle, and clinical characteristics allowed for analyses stratified by menopause status, BMI, history of chronic disease, and self-perceived overall QOL in several cancer treatment groups.
CONCLUSIONS
In summary, our study, the largest to date to characterize menopausal symptoms prospectively among premenopausal and postmenopausal Chinese women treated for primary breast cancer, identified a high prevalence of menopausal symptoms in these women. The likelihood of menopausal symptoms varied by age and menopause status at diagnosis and was highest among perimenopausal women and recently postmenopausal women. Chemotherapy was associated with menopausal symptoms among premenopausal but not postmenopausal women with breast cancer. Tamoxifen use was related to a high prevalence of all types of symptoms in both premenopausal and postmenopausal women. Poor QOL was related to a high prevalence of menopausal symptoms and modified the association of tamoxifen use with menopausal symptoms. Research on developing management and treatment strategies for menopausal symptoms among breast cancer patients is needed to improve the QOL of survivors.
